Bristol Myers Squibb, one of the biggest players in Pharma, has received approval from the U.S. Food and Drug Administration (FDA) for its new therapy ZENBEXUS (iberdomide). Zenbexus is a treatment for people with relapsed or refractory multiple myeloma.
The BMS Zenbexus therapy FDA approval brings the first cereblon E3 ligase modulating (CELMoD) therapy for patients. It is for adults with multiple myeloma who have received at least one prior line of treatment that included a proteasome inhibitor and an immunomodulatory agent.
FDA Approval For Bristol Myers Squibb’s Zenbexus Drug
The BMS Zenbexus Therapy FDA approval process used the accelerated approval pathway. This allows the FDA to approve certain medicines based on a surrogate measure that is reasonably likely to predict clinical benefit.
For Zenbexus, the supporting measure was minimal residual disease (MRD)-negative complete response. MRD refers to small amounts of cancer cells that can remain after treatment but may not be detected through conventional testing.
However, the BMS Zenbexus Therapy FDA approval is not yet the final word on clinical benefit. Continued FDA approval may depend on confirmatory trials verifying and describing the treatment’s benefit. The ongoing EXCALIBER-RRMM study is evaluating progression-free survival, or how long patients remain alive without their cancer worsening.
Bristol Myers Squibb’s Zenbexus Drug Shows Strong MRD Results
Approval for Bristol Myers Squibb’s Zenbexus drug was supported by results from the Phase 3 EXCALIBER-RRMM trial. The study compared the Zenbexus combination with daratumumab, bortezomib, and dexamethasone.
At a median follow-up of 16 months:
- 41% of patients receiving Zenbexus plus daratumumab/hyaluronidase-fihj and dexamethasone achieved an MRD-negative complete response.
- 21% of patients in the comparator group achieved the same response.
- The difference was statistically significant, with P<0.0001.
Bristol Myers Squibb chief medical officer Cristian Massacesi described the decision as meaningful progress for patients and said, “ This approval validates years of scientific research and strengthens our confidence in the potential of this approach as we continue to advance our innovative pipeline on behalf of patients with significant unmet needs.”
BMS Myeloma Drug Approval Introduces a New CELMoD Class
CELMoDs are medicines designed to modulate the cereblon protein and promote the degradation of specific proteins involved in cancer biology. Approval for Bristol Myers Squibb’s Zenbexus drug is the first therapy in this class to receive FDA approval.
The significance of the BMS Zenbexus therapy FDA approval extends beyond a single medicine because Bristol Myers Squibb is developing targeted protein degradation approaches across multiple programs. Another CELMoD, mezigdomide, is also under FDA review for relapsed or refractory multiple myeloma, with a target decision date of May 13, 2027.
BMS has also partnered with BioNTech for a $11.1 billion investment in next-generation cancer therapies. Under the agreement, the companies are co-developing and co-commercializing BioNTech’s investigational BNT327 across multiple solid tumors.
Zenbexus Safety Warnings and Side Effects
The BMS Zenbexus Therapy FDA Approval also comes with important safety warnings. Zenbexus carries a boxed warning for embryo-fetal toxicity and serious venous and arterial thromboembolism, including blood clots, heart attack, and stroke.
In the clinical study for Bristol Myers Squibb’s Zenbexus drug, neutropenia, a potentially serious reduction in infection-fighting white blood cells, occurred in 90.2% of patients. Infections occurred in 78.9%, while 7.8% discontinued Zenbexus because of adverse reactions.
Because of embryo-fetal toxicity concerns, Zenbexus is available through the restricted Zenbexus REMS program.
Blood Cancer Therapy Zenbexus Price and Availability
According to Reuters, Bristol Myers Squibb set the list price of Zenbexus at $29,500 for a 28-day cycle and expects the medicine to become available within the coming weeks. The list price does not necessarily represent the amount individual patients will pay after insurance coverage or other assistance.
For now, after the BMS Zenbexus Therapy FDA approval, the immediate focus will be on confirming whether the MRD response gives eligible patients a new oral treatment option for longer progression-free survival. The ongoing evidence will determine the longer-term regulatory position of Zenbexus.
